Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".

Voruz, Sophie; Martins, Filipe; Cairoli, Anne; Naveiras, Olaia; Homicsko, Krisztian; Missiaglia, Edoardo; de Leval, Laurence; Bisig, Bettina; Michielin, Olivier; Blum, Sabine

Voruz, Sophie; Martins, Filipe; Cairoli, Anne; Naveiras, Olaia; Homicsko, Krisztian; Missiaglia, Edoardo; de Leval, Laurence; Bisig, Bettina; Michielin, Olivier; Blum, Sabine.

Afiliação

Voruz S; Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland sophie.voruz@chuv.ch.
Martins F; Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland.
Cairoli A; Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland.
Naveiras O; Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland.
Homicsko K; Department of Oncology, University Hospital of Lausanne, Switzerland.
Missiaglia E; Institute of Pathology, CHUV, University Hospital of Lausanne, Switzerland.
de Leval L; Institute of Pathology, CHUV, University Hospital of Lausanne, Switzerland.
Bisig B; Institute of Pathology, CHUV, University Hospital of Lausanne, Switzerland.
Michielin O; Department of Oncology, University Hospital of Lausanne, Switzerland.
Blum S; Service and Central Laboratory of Hematology, University Hospital of Lausanne, Switzerland.

Haematologica ; 103(3): e130, 2018 03.

Article em En | MEDLINE | ID: mdl-29491129

Assuntos

Mesilato de Imatinib; Proteínas Tirosina Quinases; Sarcoma Histiocítico; Humanos; Piridonas; Pirimidinonas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Proteínas Tirosina Quinases / Mesilato de Imatinib Limite: Humans Idioma: En Revista: Haematologica Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Suíça

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google